Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1417 - Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: a population-based study from the Spanish Lymphoma Oncology Group (GOTEL)


08 Oct 2016


Poster Display


Maria Torrente


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


M. Torrente1, P. Sabin2, J. Gomez Codina3, L. de la Cruz Merino4, M. Llanos5, J. Guma I Padro6, C. Quero7, A. Blasco8, F.R. Garcia Arroyo9, A. Rueda10

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 3 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 4 Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla/ES
  • 5 Medical Oncology, Hospital Universitario de Canarias, santa cruz de tenerife/ES
  • 6 Medical Oncology, University Hospital St. Joan de Reus, Reus/ES
  • 7 Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 8 Medical Oncology, Hospital General Universitario Valencia, Valencia/ES
  • 9 Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra/ES
  • 10 Medical Oncology, Hospital Costa del Sol, 29602 - Malaga/ES


Abstract 1417


The optimal treatment of follicular lymphoma (FL) is not well established. There is no doubt that the clinical development of rituximab (R) has been a significant breakthrough in FL. However, its effect on overall survival (OS) in these patients is still open to debate.


We reviewed 1076 patients treated in our country diagnosed with FL. They were included in the Follicular Lymphoma Registry, a prospective registry within GOTEĹs (Spanish Lymphoma Study Group) database that includes all new lymphoma cases, regardless of their histological subtype, diagnosed in the hospitals within the Group between January 1st 1999, and January 1st 2009. Data were obtained from 16 sites. The median follow up was 54.9 months (0.13-663.12) for the entire series.


The addition of R to the chemotherapy regimen was significantly associated with a superior OS (p  60 years of age (p = 0.05); ECOG > 1 (p = 0.002); Stage III-IV (p = 0.004); more nodal and extranodal involvement (p = 0.003); > LDH (p = 0.007); and higher FLIPI (p = 0.02). Nevertheless, patients with a high-risk disease, according to the FLIPI benefited the most from the addition of R whereas statistical significance was not reached for patients with a low/intermediate FLIPI score.


In our experience, R is associated with better overall survival, especially in patients with high risk FLIPI.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario Puerta de Hierro


Spanish Lymphoma Oncology Group (GOTEL)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings